Summary of Literature for Ertapenem (Invanz)

Study Comparison Groups Objective Outcomes

Solomkin et al.

Annals of Surgery

A. Ertapenem 1 g once a day

B. Piperacillin / Tazobactam given 3.375 g every 6 hours

(Study therapies were given for a minimum of 4 days and maximum of 14 days)

Compare the clinical efficacy and safety of ertapenem Versus Piperacillin / Tazobactam in the Treatment of Complicated Intraabdominal Infections ( perforated or abscessed appendicitis were most common)

The efficacy of Ertapenem was equivalent To Piperacillin / Tazobactam in the treatment of the Intraabdominal infections

Similar safety and tolerability profile of both groups

Ertapenem may be a useful option that could eliminate the need for combination and/or multi-dosed antibiotic regimens for the empiric treatment of intra-abdominal infections

Itani et al.

The New England Journal of Medicine

A. Single dose of 1 gm of Ertapenem

B. 2 gm of Cefotetan

(Both infused over a 30-minute period within 60 minutes before the initial surgical incision)

Compare Ertapenem to Cefotetan for prophylaxis in elective colorectal surgery and appendectomy

Prophylaxis with Ertapenem was superior to prophylaxis with Cefotetan

Primary efficacy end point was the proportion of patients for whom prophylaxis was successful at the 4-week follow-up assessment after treatment

Basoli et al.

Journal of Gastrointestinal Surgery

Group A: Ertapenem (1 g/day) for 3 days

Group B: Ertapenem (1 g/day) for ≥ 5 days(To achieve balance between the treatment groups, patients

To compare Ertapenem 3 days vs. ≥5 Days in Community-Acquired Intra-abdominal Infection.

3 days of Ertapenem had the same clinical and bacteriological efficacy as a standard duration (≥5 days) of Ertapenem for the treatment of the Localized Community Acquired Intraabdominal Infections

Shorter duration of treatment can have positive impact on bacterial resistance and cost of the

were stratified according to the site of infection (complicatedappendicitis vs. all other diagnoses)

health care Larger trials are required to substantiate the

findings

Yellin et al.

International Journal of Antimicrobial Agents

Group A: Ertapenem IV 1 g once a dayGroup B: Ertapenem IV 1.5 g once a dayGroup C: Ceftriaxone IV 2 g once a day plus Metronidazole IV 500 mg every 8 hours(Primary cause of infections was appendicitis)

To compare Ertapenem mono-therapy to combination therapy with Ceftriaxone plus Metronidazole for treatment of complicated intra-abdominal infections

Response rates were: 84% (Group A) versus 85% (Group C1) and 83% (Group B) versus 77% (Group C2).

Ertapenem had a favorable dosing schedule and was as effective as the combination of Ceftriaxone plus Metronidazole in the therapy of intra-abdominal infections